Latest News

Open for applications: Vaccinology in Africa 2017, Entebbe, 24-28th April

Posted 02/02/2017

The ‘Vaccinology in Africa’ Master’s level course is now open to applications from students, researchers and professionals resident in East Africa. 40 bursaries are available for this fully funded course which covers the main aspects of human and veterinary vaccinology, the vaccine development process, biomanufacturing, clinical trials, regulatory and ethical issues, highlighting human and veterinary links and synergies. The course is jointly organised by the host institution, MUII-Plus (Makerere University-UVRI Centre of Excellence for Infection & Immunity Research and Training) in Entebbe, Uganda, and the Jenner Institute, University of Oxford. 

BBC News: Inside lab where MERS vaccine is made

Posted 20/01/2017

Scientists have named three relatively little-known diseases they think could cause the next global health emergency. A coalition of governments and charities has committed $460m to speed up vaccine development for MERS (Middle East Respiratory Syndrome), Lassa fever and Nipah virus. At the Jenner Institute, scientists are developing vaccines for all three of the viruses. Their MERS vaccine candidate is currently at the most advanced stage worldwide. It is expected that it will be trialled in humans by the end of the year. 

BMA Award: Exploiting exosomes to improve vaccines for influenza & other infectious diseases

BMA Award: Exploiting exosomes to improve vaccines for influenza & other infectious diseases

Posted 25/11/2016

Jenner Institute scientists, Dr Lynda Coughlan and Prof Adrian Hill have been awarded the 2016 British Medical Association HC Roscoe grant for a research project which aims to develop improved vaccines for influenza. Fifteen medical academics and research scientists were awarded a total of ...

UK Zika research awarded share of £120 million vaccine fund

Posted 21/11/2016

UK researchers creating new vaccines for epidemic diseases such as Zika and Ebola are among the winners of £22 million of funding, announced by the Department of Health today. These projects will be the first to benefit from the UK Vaccine Network, a £120 million fund launched last year to support Britain’s world-leading role fighting deadly diseases. The network  brings together leading figures from industry, academia and philanthropy, including the Jenner Institute, University of Oxford, the Wellcome Trust, and GlaxoSmithKline (GSK).

Now published: Jenner Newsletter - Autumn 2016

Posted 04/11/2016

In this issue, there is a particular highlight on Outbreak Pathogens. In the past months, Jenner researchers have received major funding to manufacture and clinically develop vaccine candidates against several outbreak pathogens of international concern: Zika, Chikungunya, MERS and Rift Valley Fever. Recently, the Jenner Institute has also initiated research programmes on vaccines against non-communicable diseases such as prostate cancer and psoriasis, and Prof Lucy Dorrell’s group is utilizing the Jenner Institute’s viral vector prime-boost platform to deliver therapeutic vaccine against cervical pre-cancer.

Going Viral - using viruses to fight disease

Posted 28/09/2016

'Going Viral' is the first in a new series of audio podcasts. This episode, featuring Dr Sandy Douglas from the Jenner Institute, explores how we learn to use viruses to our own advantage, in fighting them with vaccines as well as harnessing them for use in understanding how the brain is connected.

Oxford ranked first among global universities

Posted 22/09/2016

The University of Oxford ranks Number 1 in the latest Times Higher Education (THE) World University Rankings. Oxford becomes the first British university ever to occupy top position in the global table, which judges the performance of 980 universities across 79 countries.

Prof Sir Peter Ratcliffe wins Lasker research award

Posted 28/09/2016

The University of Oxford's Professor Sir Peter Ratcliffe has won the Albert Lasker Basic Medical Research Award, one of the most prestigious prizes in medicine, for his work understanding the mechanisms by which cells sense and signal hypoxia (low oxygen levels). Hypoxia is an important component of many human diseases including cancer, heart disease, stroke, vascular disease, and anaemia.

Oxford Vaccinology Courses 2016 - Now open for applications

Posted 07/09/2016
17-20 Oct: Clinical Vaccine Development and Biomanufacturing

21-25 Nov: Human and Veterinary Vaccinology

Nowhere to hide

Posted 19/07/2016

While HIV is no longer the death sentence it once was, we are yet to defeat it entirely. However, a new study from Oxford University offers hope that HIV will eventually have nowhere to hide. Tom Calver spoke to Professor Lucy Dorrell (Jenner Investigator) about her work on clearing HIV from the body.

If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.